Company Overview - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is located in Nanshan District, Shenzhen, Guangdong Province, and was established on April 21, 1998. The company was listed on May 6, 2010. Its main business involves the research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products [1] - The company's revenue composition includes: formulations 63.06%, CDMO 18.59%, heparin sodium and low molecular weight heparin raw materials 16.05%, and others 2.30% [1] Financial Performance - As of September 30, 2025, Hepalink achieved operating revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%. However, the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [2] - The company has cumulatively distributed 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [3] Stock Market Activity - On November 17, Hepalink's stock price decreased by 2.07%, trading at 12.30 yuan per share, with a total market capitalization of 18.048 billion yuan. The trading volume was 39.08 million yuan, with a turnover rate of 0.25% [1] - Year-to-date, Hepalink's stock price has increased by 17.82%, with a recent decline of 0.57% over the past five trading days and a 5.22% increase over the last 20 days [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 27,000, with an average of 0 circulating shares per person [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 12.0093 million shares, an increase of 691,700 shares compared to the previous period [3]

Core Viewpoint - Haiprime is a leading multinational pharmaceutical company with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue base [2][3]. Group 1: Company Overview - Haiprime was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The company’s main business segments include heparin, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2][7]. - As of September 30, 2025, Haiprime reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Group 2: Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The revenue composition includes 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. - Haiprime has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Group 3: Market Activity - On November 12, Haiprime's stock rose by 0.16%, with a trading volume of 39.42 million yuan and a turnover rate of 0.26%, bringing the total market capitalization to 18.165 billion yuan [1]. - The stock has seen a net outflow of 534,600 yuan from major investors today, indicating a reduction in holdings over the past three days [4][5].

Core Viewpoint - The news highlights the performance and business operations of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., emphasizing its strong international revenue and the impact of RMB depreciation on its financials [2][3]. Company Overview - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms [2]. - The company's main business includes the heparin industry chain, biopharmaceutical CDMO, and the investment, development, and commercialization of innovative drugs [2][7]. - As of September 30, 2025, the company reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The revenue composition includes 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On November 10, the stock price of Hepalink increased by 0.90%, with a trading volume of 45.0469 million yuan and a turnover rate of 0.29%, bringing the total market capitalization to 18.15 billion yuan [1]. - The stock has seen a net outflow of 1.201 million yuan from major funds today, indicating a lack of strong buying interest [4][5]. Technical Analysis - The average trading cost of the stock is 11.57 yuan, with the current price near a support level of 12.33 yuan, suggesting potential for a rebound if this level holds [6].

Core Viewpoint - The news highlights the performance and business operations of Haiprime, a leading multinational pharmaceutical company in China, focusing on its revenue structure, market position, and recent financial results. Company Overview - Haiprime was established in 1998 and is headquartered in Shenzhen, China, with a dual financing platform (A+H shares) [2] - The company specializes in the heparin industry chain, biopharmaceutical CDMO services, and the investment, development, and commercialization of innovative drugs [2][7] - As of September 30, 2025, Haiprime reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7] Revenue Composition - The revenue composition of Haiprime is as follows: 63.06% from formulations, 18.59% from CDMO services, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7] Market Performance - On November 7, Haiprime's stock rose by 0.91%, with a trading volume of 41.4586 million yuan and a turnover rate of 0.27%, bringing the total market capitalization to 17.989 billion yuan [1] - The company benefits from a high overseas revenue ratio of 93.04%, which is positively impacted by the depreciation of the Chinese yuan [3] Shareholder Information - As of September 30, 2025, Haiprime had 27,000 shareholders, an increase of 2.60% from the previous period [7] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 12.0093 million shares, an increase of 691,700 shares from the previous period [9] Dividend Distribution - Since its A-share listing, Haiprime has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8]

证券之星消息，11月5日，海普瑞（002399）融资买入319.5万元，融资偿还243.99万元，融资净买入 75.5万元，融资余额2.68亿元，近3个交易日已连续净买入累计1317.81万元，近20个交易日中有11个交 易日出现融资净买入。 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-11-05 | 75.50万 | 2.68亿 | 1.77% | | 2025-11-04 | 236.41万 | 2.68亿 | 1.77% | | 2025-11-03 | 1005.89万 | 2.65亿 | 1.72% | | 2025-10-31 | -134.37万 | 2.55亿 | 1.68% | | 2025-10-30 | 49.68万 | 2.57亿 | 1.74% | 融券方面，当日融券卖出4500.0股，融券偿还3.0万股，融券净买入2.55万股，融券余量8.67万股，近20 个交易日中有11个交易日出现融券净卖出。 | 交易日 | 融券净卖出(股) | | 融券余量(股) | 融券余额(元) | | - ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 深圳市海普瑞藥業集團股份有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09989 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 220,094,500 | RMB | | 1 | RMB | | 220,094,500 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 220,094,500 | RMB | | 1 | RMB | | 220,094,500 | 本月底法定/註冊股本總額： RMB 1,467,296,204 ...

Core Insights - Haiprui (002399.SZ) reported its Q3 2025 results on October 31, 2025, highlighting significant institutional investor holdings [1] Institutional Holdings - As of October 30, 2025, seven institutional investors disclosed holding a total of 1 billion shares of Haiprui, representing 68.14% of the company's total equity [1] - The institutional investor group includes Shenzhen Lerun Technology Co., Ltd., Gongqingcheng Jintian Soil Investment Partnership (Limited Partnership), Gongqingcheng Water Droplet Stone Investment Partnership (Limited Partnership), Gongqingcheng Feilai Stone Investment Co., Ltd., Shenzhen Haiprui Pharmaceutical Co., Ltd. - Second Employee Stock Ownership Plan, Hong Kong Central Clearing Limited, and Shenzhen Haiprui Pharmaceutical Group Co., Ltd. - Third Employee Stock Ownership Plan [1] - Compared to the previous quarter, the total institutional holding percentage decreased by 0.44 percentage points [1] Public Fund Activity - In this period, 92 public funds were not disclosed compared to the previous quarter, including Southern CSI 1000 ETF, Huaxia CSI 1000 ETF, GF CSI 1000 ETF, GF CSI All-Index Medical and Health ETF, and Fortune CSI 1000 ETF [1] Foreign Investment - One foreign fund, Hong Kong Central Clearing Limited, increased its holdings compared to the previous period, with a slight increase in shareholding percentage [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002399 证券简称：海普瑞 公告编号：2025-030 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 R否 （二） 非经常性损益项目和金额 R适用 □不适用 单位：元 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度财务会计报告是否经过审计 □是 R否 其他符合非经常性损益定义的损益项目的具体情况： □适用 R不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □适用 R不适用 公司不存在将《公开发行证券的公司信息披露解释性公 ...

格隆汇10月30日丨海普瑞(002399.SZ)发布公告，2025年前三季度，实现营业收入41.94亿元，同比增加 3.09%；归属于上市公司股东的净利润5.54亿元，同比减少29.04%；归属于上市公司股东的扣除非经常 性损益的净利润5.52亿元，同比增加28.69%；基本每股收益0.3773元。 ...

智通财经APP讯，海普瑞(09989)发布2025年第三季度报告，截止2025年9月30日止9个月，该公司取得营 业收入41.94亿元人民币，同比增加3.09%;归属于上市公司股东的净利润5.54亿元，同比减少29.04%;基 本每股收益0.3773元。 ...